Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomised phase III trial of De Gramont schedule 5-fluorouracil and leucovorin plus irinotecan versus single agent irinotecan, plus or minus celecoxib in patients with previously treated metastatic colorectal cancer.

Trial Profile

Randomised phase III trial of De Gramont schedule 5-fluorouracil and leucovorin plus irinotecan versus single agent irinotecan, plus or minus celecoxib in patients with previously treated metastatic colorectal cancer.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Irinotecan (Primary) ; Fluorouracil; Folinic acid
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms DaVINCI

Most Recent Events

  • 07 Dec 2010 Trial location (Australia) identified as reported by Australian New Zealand Clinical Trials Registry.
  • 07 Dec 2010 New source identified and integrated (Australian New Zealand Clinical Trials Registry).
  • 05 Nov 2010 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top